Abstract: The specification describes an artificial resuscitation bag (5) having (i) a deformable bag (54) with a gas inlet (54A) and a gas outlet (54B), (ii) a pneumatic control valve (50) comprising an exhaust port (50c) adapted for controlling the flow of gas exiting to the atmosphere through said exhaust port (50c), and (iii) a monitoring module (60), operably connected to the pneumatic control valve (50) and having an absolute pressure sensor (60d) for measuring at least an absolute pressure (Pabs) in the inner compartment (50f) of the pneumatic control valve (50) and for transmitting at least an absolute pressure signal to a central processing unit (60c) and an ambient pressure sensor (60b) for measuring at least an atmospheric pressure (Patm) and for transmitting at least an atmospheric pressure signal to the central processing unit (60c).

Abstract: The invention relates to a gas distribution assembly comprising a gas container (20), such as a gas cylinder, a valve unit fixed to the gas container (20) and a protective cap (1, 2, 3, 4) arranged around the said valve unit, the protective cap (1, 2, 3, 4) comprising an opening (9) in which a rotary control member (5) is housed. The opening (9) is bordered by a protruding brim (7) jutting out from the external surface of the body (2) of the protective cap (1, 2, 3, 4). The protruding brim (7) comprises a cutout (8) forming a reading window so that marks or markings (11) corresponding to gas flow-rate values can be read.

Abstract: Microbicidal preparations containing a) at least one 1,2-benzisothiazolin-3-one or its derivatives; b) at least one 2-mercaptopyridine N-oxide, or its salts and derivatives; c) at least one aromatic alcohol; and d) at least one alkalinizing agent, or a preparation prepared by mixing components a) to d), and having a pH of at least 11, are provided. The microbicidal preparations are clear and storage-stable, and are suitable for use as preservatives.

Abstract: The invention relates to a system for storing and distributing a gaseous mixture formed of NO/N2, comprising a container (6) containing an NO/nitrogen mixture equipped with an in-built pressure regulator (8) with an internal passage (22) for gas made of stainless steel and means for regulating the expansion of the gas collaborating with an expansion valve (27) and a valve seat (28) made of stainless steel. A first outlet coupling (21a) referred to as a ‘pressure’ outlet delivers the gas at low pressure and a second outlet coupling (21b) associated with a flow meter device comprising calibrated orifices and a flow rate selection member delivers the gas at several different flow rates. The invention also relates to an installation for distributing a gas containing NO to a patient comprising a ventilator (1) delivering a gas containing oxygen and to a system for storing and distributing a gaseous mixture formed of NO/N2 according to the invention.

Abstract: The invention concerns a method of storing a NO/N2 mixture in a packaging container, in particular a gas bottle, having an internal volume less than or equal to 12 liters, characterized in that a NO/N2 gaseous mixture containing between 400 ppm and 1000 ppm by volume of NO and nitrogen for the remainder is held at a pressure of at least 250 bar in the internal volume of said container. Preferably, the NO/N2 gaseous mixture is held at a pressure of 280 to 450 bar, and preferably between 300 and 420 bar.

Abstract: Method for reducing the formaldehyde emission of a composition containing a formal by adding urea, urea derivatives, amino acids, guanidine or guanidine derivatives.

Abstract: A stabilizer composition having (a) one or more 1- or 2-(C1- to C24-alkyl) glycerol ethers (glycerol monoalkyl ethers) and (b) a mixture of at least two different aromatic alcohols (b1, b2) chosen from the groups of i) aryloxyalkanols, ii) arylalkanols and iii) oligoalkanol aryl ethers, where the two different aromatic alcohols belong to different groups i), ii) and iii).

Abstract: A concentrate for cleaning and disinfecting includes (i) one or more alkyl alcohol alkoxylates, (ii) one or more formaldehyde donor compounds, (iii) optionally one or more biocidal, in particular fungicidal, active ingredient(s), (iv) optionally one or more glycols and (v) optionally up to 10% by weight of water. Concentrates according to the invention can be formulated with a high content of formaldehyde donor compound without an undesired formaldehyde odor arising.

Abstract: A preservative which comprises a) one or more isothiazolones and b) one or more glycerol monoalkyl ethers, and the use of the preservative for microbicidal finishing of cosmetic and pharmaceutical products.

Abstract: The disclosure describes a technique for monitoring patient utilization of inhaled Nitric Oxide as well as waste exhaust of Nitric Oxide in gases exhaled from patient lungs. By monitoring the real dose provided to a patient, actual compliance with therapeutic target doses may be monitored to improve patient safety and therapeutic benefit from inhaled Nitric Oxide. Simultaneously, unnecessary waste of inhaled Nitric Oxide may be avoided thereby increasing the cost effectiveness of Nitric Oxide therapy. The minimization of Nitric Oxide waste has the further benefit of reducing environmental Nitrogen Dioxide levels in e.g. a NICU environment thereby mitigating medical personnel's Nitrogen Dioxide exposure.

Abstract: The disclosure describes a technique for monitoring patient utilization of inhaled Nitric Oxide as well as waste exhaust of Nitric Oxide in gases exhaled from patient lungs. By monitoring the real dose provided to a patient, actual compliance with therapeutic target doses may be monitored to improve patient safety and therapeutic benefit from inhaled Nitric Oxide. Simultaneously, unnecessary waste of inhaled Nitric Oxide may be avoided thereby increasing the cost effectiveness of Nitric Oxide therapy. The minimization of Nitric Oxide waste has the further benefit of reducing environmental Nitrogen Dioxide levels in e.g. a NICU environment thereby mitigating medical personnel's Nitrogen Dioxide exposure.

Abstract: The disclosure describes a technique for monitoring patient utilization of inhaled Nitric Oxide as well as waste exhaust of Nitric Oxide in gases exhaled from patient lungs. By monitoring the real dose provided to a patient, actual compliance with therapeutic target doses may be monitored to improve patient safety and therapeutic benefit from inhaled Nitric Oxide. Simultaneously, unnecessary waste of inhaled Nitric Oxide may be avoided thereby increasing the cost effectiveness of Nitric Oxide therapy. The minimization of Nitric Oxide waste has the further benefit of reducing environmental Nitric Oxide and Nitrogen Dioxide levels in e.g. a NICU environment thereby mitigating medical personnel's Nitric Oxide and Nitrogen Dioxide exposure.

Abstract: The disclosure describes a technique for monitoring patient utilization of inhaled Nitric Oxide as well as waste exhaust of Nitric Oxide in gases exhaled from patient lungs. By monitoring the real dose provided to a patient, actual compliance with therapeutic target doses may be monitored to improve patient safety and therapeutic benefit from inhaled Nitric Oxide. Simultaneously, unnecessary waste of inhaled Nitric Oxide may be avoided thereby increasing the cost effectiveness of Nitric Oxide therapy. The minimization of Nitric Oxide waste has the further benefit of reducing environmental Nitrogen Dioxide levels in e.g. a NICU environment thereby mitigating medical personnel's Nitrogen Dioxide exposure.

Abstract: Cooling lubricant (concentrate or solution) comprising a cooling lubricant base based on mineral and/or synthetic oil and preservative comprising (a) one or more 1- or 2-(C3 to C24 alkyl)glyceryl ethers.

Abstract: The invention relates to the use of argon gas for producing all or part of an inhalable medicinal product intended to prevent or treat a neurointoxication in humans. The medicinal product contains argon in an effective proportion and acts on at least one brain receptor in order to regulate the functioning of dopamine-, glutamate-, serotonin-, acetylcholine-, taurine-, GABA- and/or noradrenalin-mediated neurotransmission systems. Preferably, the proportion by volume of argon in the gaseous medicinal product is between 15 and 80%. The neurointoxication is chosen from excitotoxicities engendering a state of addiction, acute cerebral accidents, neurodegenerative diseases, and psychiatric or neurological pathologies, in particular anxiety conditions, psychotic conditions, in particular schizophrenia, and epilepsy in its various forms.

Abstract: A method of preserving a cosmetic product by adding to the cosmetic product a concentrate, which may be in anhydrous form, which includes (a) 1-(2-ethylhexyl) glycerol ether, and (b) one or more aromatic alcohols, (a) and (b) having a weight ratio of (a)/(b) is less than or equal to 0.15.

Abstract: Method for reducing the formaldehyde emission of a composition containing a formal by adding urea, urea derivatives, amino acids, guanidine or guanidine derivatives.

Abstract: An aqueous-based composition which includes a) at least one bispyridinium alkane (for example octenidine) and b) at least one stabilizer selected from antioxidants, complexing agents, reducing agents, UV filters and photoprotective agents, in particular ?-tocopherol, and BHT. The composition can also include c) one or more auxiliaries selected from, for example, nonionic surfactants, ethers, solvents and polymers, in particular fatty alcohol alkoxylates and alkoxylated fatty acid monoglycerides. The presence of the stabilizer reduces or prevents the appearance of decomposition products of bispyridinium alkanes and, in the case of the presence of auxiliaries, of decomposition products of the auxiliaries, such as ethers and peroxides.

Abstract: Compositions having a combination a) of one or more glycerol monoalkyl ether(s) of the general formula R—O—CH2—CHOH—CH2OH in which R is a branched or unbranched C3-C18-alkyl group, where the alkyl group can be substituted by one or more hydroxyl and/or C1-C4-alkoxy group(s) and/or the alkyl chain can be interrupted by up to four oxygen atoms, with b) an antioxidant or two or more antioxidants as stabilizer(s), the simultaneous presence of phosphocholines and phosphocholine derivatives being excluded.

Abstract: A valve system (5) connectable to a fluid channel (3), wherein the valve system (5) includes an actuating element (33) and a closing element (17) for selectively closing and opening of the channel (3), wherein the valve system (5) includes a chamber (15) and a movable coupling member (37), wherein at least one section (48) of the coupling member (37) is located within the chamber (15) and the coupling member (37) is capable of moving under its gravitational force into a transfer position in which the coupling member (37) may transfer to the closing element (17) an external force acting on the actuating element (33) towards the closing element (17).